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Influenza B virus causes considerable disease burden worldwide annually, highlighting the limitations of current
influenza vaccines and antiviral drugs. In recent years, broadly neutralizing antibodies (bnAbs) against hemag-
glutinin (HA) have emerged as a new approach for combating influenza. We describe the generation and char-
acterization of a chimeric monoclonal antibody, C12G6, that cross-neutralizes representative viruses spanning
the 76 years of influenza B antigenic evolution since 1940, including viruses belonging to the Yamagata, Victoria,
and earlier lineages. Notably, C12G6 exhibits broad cross-lineage hemagglutination inhibition activity against influ-
enza B viruses and has higher potency and breadth of neutralization when compared to four previously reported
influenza B bnAbs. In vivo, C12G6 confers stronger cross-protection against Yamagata and Victoria lineages of in-
fluenza B viruses in mice and ferrets than other bnAbs or the anti-influenza drug oseltamivir and has an additive
antiviral effect when administered in combination with oseltamivir. Epitope mapping indicated that C12G6 targets a
conserved epitope that overlaps with the receptor binding site in the HA region of influenza B virus, indicating why
it neutralizes virus so potently. Mechanistic analyses revealed that C12G6 inhibits influenza B viruses via multiple
mechanisms, including preventing viral entry, egress, and HA-mediated membrane fusion and triggering antibody-
dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity responses. C12G6 is therefore a
promising candidate for the development of prophylactics or therapeutics against influenza B infection and may
inform the design of a truly universal influenza vaccine..org
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/INTRODUCTION
Seasonal influenza caused by influenza A H3N2 and H1N1 subtypes
and influenzaBYamagata andVictoria lineages remains a serious threat
to health worldwide (1). Although influenza A has garnered much at-
tention because of its pandemic association, the clinical presentations
and complications of seasonal influenza A and B virus infections are
clinically indistinguishable (2). A recent increase in the rate of influenza
B infections has resulted in higher morbidity and mortality worldwide
compared to that observed for influenza A H1N1 (3, 4). This situation
highlights the limitations of current influenza vaccines and antiviral
drugs in combating influenza B. Currently circulating influenza B
viruses originated in the 1940s and evolved into two genetically and an-
tigenically distinct lineages in the 1980s, the Victoria lineage and the
Yamagata lineage (5). The continuous cocirculation of both influenza
B virus lineages with influenza A/H3N2 and A/H1N1 viruses during
seasonal epidemics has prompted the development of quadrivalent vac-
cines that include strains from both influenza B lineages (6). However,
current influenza vaccines struggle to induce sufficient levels of cross-reactive neutralizing antibodies, and vaccine strains frequently become
mismatched from continuously evolving influenza variants (7, 8). In ad-
dition, the effectiveness of existing antiviral drugs for the treatment of
influenza infection is limited because of short treatment windows and
emerging antiviral drug resistance (9). Thus, there is an unmet medical
need to develop more effective universal prophylactic and therapeutic
approaches against influenza infection.
Passive immune protection using broadly neutralizing antibodies
(bnAbs) that target vulnerable conserved epitopes is a promising ap-
proach for treating highly variable viral infections (10). The hemag-
glutinin (HA) protein, which is the major influenza viral surface
glycoprotein responsible for binding cellular receptors, is a common
target of influenza bnAbs. This protein can be bound by neutralizing
antibodies to prevent the propagation of influenza virus via distinct
mechanisms (11).Most previously described anti-HAbnAbs are specific
for conserved epitopes in theHAstem region (12–14). In contrast, only a
small number of HA bnAbs targeting the HA head region have been
characterized due to the higher variability in this region. Because epi-
topes on the HA head are critical for virus infection andmore accessible
than those on the HA stem, the development of HA head–specific
bnAbs targeting the vulnerable receptor binding site (RBS) is desirable.
Although most anti-HA bnAbs have targeted influenza A (15), the
recent isolation of anti-HA bnAbs targeting influenza B revealed the
presence of similar conserved HA head and stem epitopes on two phy-
logenetically and antigenically distinct influenza B virus lineages (16–18).
The CR8033 bnAb described by Dreyfus et al. (17), which is directed at
the RBS epitope on the HA head, showed better prophylactic effects in
vivo than bnAbs directed at HA epitopes near the stem, such as CR80711 of 12






andCR9114.Mechanistic analysis indicated that CR8033 prevented viral
entry and egress, whereas CR8071 only prevented viral egress; antibodies
having multiple neutralizing mechanisms understandably provide more
comprehensive antiviral activities (17). Notably, whereas CR8033 targets
a conserved site in the influenza B virus HA, this epitope is not identical
in function for both lineages of influenza B viruses, with CR8033 only
inhibiting viral entry of Yamagata lineage viruses. Therefore, generation
of novel bnAbs directed at conserved HA head epitopes associated with
viral entry in both influenza B lineages viruses is necessary.
The difficulty in developing bnAbs against theHA head of influenza
lies in the diverse antigenicity of the different subtypes or lineages of
influenza viruses and the highly variable epitopes on the HA head.
To address this, we trialed various immunization regimens to induce
cross-reactive antibodies in mice against highly conserved epitopes in
the HA protein of influenza B and used a functional screening strategy
to select antibodies that have multiple inhibiting mechanisms. Using
these optimized immunization and screening protocols, one antibody,
designated 12G6, was identified, and a chimeric version containing a
human immunoglobulin G1 (IgG1) Fc fragment was generated (C12G6).
The potent and broad-spectrum antiviral effects of C12G6 were char-
acterized in vitro and in vivo, indicating thatC12G6may be a promising
candidate for the development of a high-efficacy universal prophylactic





A multimechanistic bnAb against influenza B was generated
by sequential immunization
To generate bnAbs against conserved functional epitopes in the HA
head of influenza B, we implemented eight distinct immunization regi-
mens in mice. The mice were sequentially immunized intranasally or
subcutaneously with two representative influenza B live viruses, FL/
2006 (B/Florida/4/2006, Yamagata) and BR/2008 (B/Brisbane/60/2008,
Victoria) (fig. S1A). Enzyme-linked immunosorbent assay (ELISA)
screening against FL/2006 and BR/2008 identified 10 cross-lineage reac-
tive antibodies from a total of 318 influenza B–specific antibodies gener-
ated frommice of groups 3 (12G6, 3G8, 4E7, 5C9, 7G8, 10F8, and 10H6
antibodies), 4 (13E6 and 13C2 antibodies), and 7 (13D8 antibody) (fig.
S1B). Then, to generate efficient bnAbs that are able to block infection of
both lineages of influenza B virus, we performed the hemagglutination
inhibition (HI) assay in the second screening round. Three of the 10 anti-
bodies (12G6, 3G8, and 10F8) showed cross-lineage HI activity against
both lineages (fig. S1C).We further determined the activity of these three
antibodies against BR/2008 by three other functional assays. As expected,
12G6, 3G8, and 10F8 antibodies effectively neutralized the BR/2008
(fig. S1D). Of these, 12G6 and 10F8 antibodies efficiently inhibited low
pH–induced viral fusion with endosomal membranes (fig. S1E), and
specifically, only 12G6 exhibited antibody-dependent cell-mediated cy-
totoxicity (ADCC) activity against BR/2008 (fig. S1F). Because the 12G6
cross-reacted with both lineages of influenza B viruses and inhibited the
viruses through multiple mechanisms, it was studied further.
12G6 was purified from mouse ascites and demonstrated reactivity
against 18 virus strains representing the three distinct influenza B
lineages in ELISA, HI, and MN (microneutralization) assays (fig. S2
and table S1). The DNA sequences of the VH (variable region of immu-
noglobulin heavy chain) and VL (variable region of immunoglobulin
light chain) regions of 12G6were obtained and comparedwith the closest
germline sequences using the VBASE2 database (www.vbase2.org/), and
themutation rates of the nucleotides in theDNAsequences of theVHandShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017VL are 7.14% (21 of 294) and 2.48% (7 of 282), respectively (fig. S3). To
further evaluate thepotential clinical use of 12G6, a chimeric 12G6mono-
clonal antibody (mAb), designated C12G6, which contains the variable
region of mouse 12G6 and the human IgG1 Fc region, was constructed
and characterized in subsequent in vitro and in vivo experiments.
C12G6 broadly neutralizes all available influenza B viruses
isolated since 1940
To determine the breadth of C12G6 activity against influenza B viruses,
we tested purified C12G6 for the activity against a panel of 18 available
influenza B virus strains from distinct lineages (table S2). The diversity
of these representative strains is illustrated by a dendrogram of the full-
length nucleotide sequences of their respective HA genes (Fig. 1A). In a
primary binding test, 10 representative purified influenza B viruses were
used, and C12G6 reacted with all of them, with half maximal effective
concentration (EC50) values ranging from 7.68 to 60.39 ng/ml. In con-
trast, the control antibody C5G6 (a chimeric mAb against 2009 pan-
demic H1N1 influenza A viruses) did not bind to any influenza B
viruses but did bind A/California/04/2009 control (Fig. 1B and table
S3). In addition, binding of C12G6 IgG to recombinant HA (rHA) pro-
teins of two representative influenza B strains was measured by surface
plasmon resonance, with the rHAs of the two strains both being strongly
bound by C12G6: Kd (dissociation constant) = 0.858 nM for Yamagata
rHA; Kd = 2.26 nM for Victoria rHA (fig. S4 and table S4). Consistent
with its ability to bind to a panel of influenza B viruses, C12G6 also binds
to B/Florida/4/2006 (Yamagata)– and B/Brisbane/60/2008 (Victoria)–
infected Madin-Darby canine kidney (MDCK) cells, when tested by
immunofluorescence assay, flow cytometry, orWestern blotting against
the B/Florida/4/2006 HA proteins (figs. S5 to S7).
To further compare the functional activities of C12G6 with those of
four previously described cross-lineage neutralizing influenza B HA–
specific bnAbs (16, 17), chimeric versions of them were constructed
and prepared, being designated CR8033-like, CR8071-like, CR9114-
like, and 5A7-like, respectively (fig. S8A). We confirmed that these chi-
meric mAbs all showed binding activity against both influenza B virus
lineages (fig. S8B and table S5). Next, we directly compared the in vitro
HI and neutralization activities and breadth of reactivity of C12G6 with
those of the four reported antibodies. CR8033-like antibody displayed
HI activity against Yamagata and earlier lineage strains, but notVictoria
viruses. The CR8071-like, CR9114-like, 5A7-like, and C5G6 antibodies
did not exhibit HI activity against any influenza B strain. In contrast,
C12G6 showed specific HI activity against all 18 influenza B viruses
tested (Fig. 1C). In the MN assay, C12G6, CR8033-like, CR8071-like,
and 5A7-like antibodies neutralized both lineage virus strains, although
there were differences in both potency and breadth of reactivity (Fig.
1D, fig. S9, and tables S6 to S8). C12G6 was the only antibody tested
that had neutralizing activity against all the representative viruses, with
a median IC50 of 1.40 mg/ml. The CR8033-like antibody failed to neu-
tralize the Victoria virus strain B/Rhode Island/01/2012–like, whereas
the CR8071-like antibodywas unable to neutralize the three earlier line-
age strains (B/Lee/1940, B/Great Lakes/1739/1954, and B/Singapore/3/
1964) or the Victoria lineage strain (B/New York/1352/2012–like). The
5A7-like antibody weakly neutralized only one of the five Yamagata
lineage virus strains tested (B/Florida/4/2006) and 3 of the 10 Victoria
lineage strains tested (B/Hong Kong/330/2001, B/Malaysia/2506/2004,
and B/Brisbane/60/2008). IC50 values are detailed in fig. S9. Median
IC50 values were 1.40, 1.97, 10.42, and 34.22 mg/ml for C12G6,
CR8033-like, CR8071-like, and 5A7-like antibodies, respectively,
when non-neutralized viruses were excluded from the evaluation. Thus,2 of 12
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in addition to greater neutralization breadth, C12G6 also exhibits greater
neutralization potency than the four reported influenza B bnAbs.
C12G6 shows broad prophylactic and therapeutic activity in
mice and ferrets
Three mouse-adapted (MA) influenza B viruses, MA-B/Florida/4/2006
(Yamagata lineage), MA-B/Brisbane/60/2008 (Victoria lineage), and
MA-B/Lee/1940 (earlier lineage) generated in our laboratory were used
to evaluate the prophylactic and therapeutic antiviral activities of
C12G6 in vivo. For the evaluation of cross-protection of C12G6 inmice,
a dose-ranging study was carried out by intravenously administering
various single doses of each antibody 1 day before (prophylactic groups)
or after (therapeutic groups) intranasal virus challenge. C12G6 showedShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017considerable prophylactic and therapeutic efficacies against lethal chal-
lenge with all three representative influenza B viruses (Fig. 2). For the
prophylactic groups, C12G6 doses greater than 1 mg/kg fully protected
mice against infection with all three viruses, with animals in these
groups all gaining weight by the end of the study (fig. S10, A to C). Even
C12G6 (0.06 mg/kg) still partially protected mice from lethal infection
with the three virus strains (Fig. 2, A to C). For the therapeutic groups,
mice treated with a single dose of C12G6 (5 or 10 mg/kg) 1 day after
infection all survived lethal challenge with each of the three representa-
tive MA influenza B viruses. A single dose as low as 0.2 mg/kg still
provided partial protection against all viruses (Fig. 2, D to F). Reduced
weight loss was also observed, compared to the IgG control (fig. S10, D
to F). Consistent with the survival data, lung viral titers in both MA-B/Fig. 1. In vitro binding and neutralization activities of C12G6. (A) Dendrogram of all nonredundant, full-length influenza B HA sequences from the National Center
for Biotechnology Information (NCBI) Flu database. The Yamagata lineage strains are labeled within blue boxes, the Victoria lineage strains are labeled within red boxes,
and the earlier lineage strains (influenza B strains isolated before the 1980s) are labeled within purple boxes. (B) Binding (EC50 ELISA values) of C12G6 antibody to
representative purified viruses from the three influenza B lineages. EC50 values above 10
4 ng/ml (dashed line) were scored as negative. (C) Fifty percent inhibitory
concentrations [IC50s (micrograms per milliliter)] of the indicated antibodies against representative strains from the three influenza B lineages were determined by
performing HI assays. The values are representative of three independent experiments. The values below 50 mg/ml are color-filled: red, strong reactivity; yellow, mod-
erate reactivity; light blue, weak reactivity; >50, negative reactivity. (D) Average IC50 values of the indicated antibodies were determined from three independent
neutralization experiments using a panel of 18 influenza B virus strains, each plotted as a single symbol. The negative control was C5G6, a chimeric influenza A antibody
containing a human IgG1 Fc fragment, CA/2009, a control influenza A virus. Full viral strain designations are listed in table S2.3 of 12
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Florida/4/2006 or MA-B/Brisbane/60/2008 infections were consid-
erably reduced in mice receiving C12G6 compared to those given con-
trol IgG (Fig. 2, G and H). Hematoxylin and eosin staining results and
immunohistochemical staining analysis (using an anti–influenza B nu-Shen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017cleoprotein mAb, 4D5, generated by our
laboratory and validated in fig. S11) indi-
cated that prophylactic and therapeutic
treatment with C12G6 also decreased the
lung damage caused by both influenza B
virus lineages, compared to the control
IgG–treated group (figs. S12 and S13).
To extend the evaluation, we directly
compared the in vivo therapeutic efficacy
of C12G6 in mice with that of the four re-
ported bnAbs and the anti-influenza drug
oseltamivir. All mice receiving C12G6
survived lethal challenge with both influ-
enza B lineage strains. In contrast, 80, 60,
0, 20, or 0% of mice survived infection
with the Yamagata virus strain MA-B/
Florida/4/2006 1 day before receiving
CR8033-like (2 mg/kg), CR8071-like
(2 mg/kg), CR9114-like (2 mg/kg), 5A7-
like (2mg/kg), orC5G6 (2mg/kg) antibody,
respectively (Fig. 3A). For the Victoria
strain MA-B/Brisbane/60/2008, the same
doses of CR8033-like, CR8071-like, CR9114-
like, 5A7-like, or C5G6 antibody protected
60, 40, 0, 20, or 0% of mice, respectively
(Fig. 3B). Reduced weight loss in C12G6-
treated mice also reflected the better pro-
tective potency of C12G6 when compared
to the other influenza B–specific bnAbs
(Fig. 3, C and D). Consistent with the sur-
vival and body weight data, at day 3 after
infection, viral titers of both MA-B/Florida/
4/2006 and B/Brisbane/60/2008 were con-
siderably lower in the lungs of C12G6-
treated mice than in those treated with the
four reported bnAbs (Fig. 3, E and F).
For the comparison with oseltamivir,
we administered a single dose of C12G6
(10 mg/kg) or two doses of oseltamivir
(25 mg/kg) a day for 4 consecutive days
at different timepoints after infectionwith
MA-B/Florida/4/2006 or MA-B/Brisbane/
60/2008 virus. As expected, all control ani-
mals died by day 10 after infection. When
administered 1 day after infection, C12G6
treatment resulted in 100% survival and lit-
tle weight loss for both virus lineage strains,
whereas oseltamivir only partially protected
animals, with survival rates of 60 and 40%
with marked weight loss for the Yamagata
and Victoria strains, respectively (Fig. 4, A
and B, and fig. S14). Survival rates of 80%
were achieved even when treatment with
C12G6 was delayed until 3 days after infec-
tion with either influenza B virus lineage.Encouragingly, more than 50% of mice survived after treatment with
C12G6 at 5 days after infection with either virus. In contrast, all mice
treated with control IgG or with oseltamivir at 3 or 5 days after infec-
tion died by 10 days after infection (Fig. 4, A and B).Fig. 2. In vivo prophylactic and therapeutic efficacy of C12G6 in mice. (A to C) Prophylactic efficacy of C12G6
against lethal challenge with 25 MLD50 (50% mouse lethal dose) of MA-B/Florida/4/2006 (A), MA-B/Brisbane/60/
2008 (B), or MA-B/Lee/1940 virus (C). The survival curves of BALB/c mice (n = 5 per group) treated with C12G6
(5, 1.7, 0.6, 0.2, or 0.06 mg/kg) or C5G6 (20 mg/kg) 1 day before lethal challenge are shown. (D to F) For the therapeutic
groups, survival curves for BALB/c mice (n = 5 per group) that received C12G6 (10, 5, 1, or 0.2 mg/kg) or C5G6 (20 mg/kg)
1 day after lethal challenge with 25 MLD50 of MA-B/Florida/4/2006 (D), MA-B/Brisbane/60/2008 (E), or MA-B/Lee/1940 (F)
virus are shown. (G and H) The virus titers in the lungs of the mice treated with C12G6 (5 mg/kg) prophylactically (G) or
C12G6 (10 mg/kg) therapeutically (H) were determined on days 3 and 6 after infection. The control IgG is C5G6. The black
bars indicate mean values. The log-rank test was used to assess the significance (*P < 0.05) of survival outcome, and the
t test was used to determine the significance of virus titers in the lungs compared to the control IgG–treated group. *P <
0.05 and ***P < 0.001. TCID50, median tissure culture infectious dose.4 of 12
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owDespite the efficacy of oseltamivir being limited, especially when the
treatment is delayed, severely ill influenza patients are generally given
oseltamivir upon hospital admission. Therefore, we tested whether
coadministration of C12G6 and oseltamivir provided better protective
efficacy than either treatment alone. Mice infected with MA-B/Florida/
4/2006 or MA-B/Brisbane/60/2008 were treated, starting at 48 hours
after infection, with C12G6, oseltamivir, or a combination of these
two therapies. Mice receiving oseltamivir plus control C5G6 antibody
exhibited 100% mortality by day 9 after lethal challenge with both
lineages of influenza B virus, similar to the control group (C5G6 plus
water). Administration of C12G6 plus water only partially protected
animals, with survival rates of 40 and 60% for the Yamagata andVictoria
strains, respectively. In contrast, coadministration of C12G6 with
oseltamivir completely protected mice after lethal challenge with the
two influenza B virus lineages (Fig. 4, C and D). Coadministration also
resulted in reduced weight loss in mice, compared to treatment with
either active agent alone (Fig. 4, E and F). Finally, consistent with the
survival and bodyweight data, combined treatment considerably reducedShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017lung viral titers at days 4 and 6, compared with C12G6 or oseltamivir
alone (Fig. 4, G and H).
To further estimate the protective potential of C12G6 in vivo, we
determined the prophylactic and therapeutic windows for treating fer-
rets infectedwith B/Florida/4/2006 (Yamagata lineage) or B/Brisbane/
60/2008 (Victoria lineage). As expected, nasal wash viral titers for fer-
rets treatedwithC12G6 either prophylactically or therapeutically were
considerably lower than for those treated with control antibody, for
both virus infections (Fig. 5, A to D). In addition, C12G6 treatment
resulted in fever reduction after infection with each of the two viruses,
in comparison to control antibody–treated animals (Fig. 5, E to H).
Moreover, infected animals administered C12G6 only experienced
slight body weight loss; in contrast, considerable body weight loss
was observed in control antibody–treated animals (fig. S15). Con-
sistent with the data above, all control ferrets showed clinical signs
of infection, including nasal discharge, sneezing, and inactivity,
whereas a lesser proportion of ferrets treated with C12G6 displayed







Fig. 3. Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice. (A to F) Survival curves (A and B), body weight change (C and D), and lung viral
titers (E and F) for BALB/c mice (n = 5 per group) treated intravenously with antibodies (2 mg/kg), indicated 24 hours after lethal challenge with 25 MLD50 of MA-B/
Florida/4/2006 or B/Brisbane/60/2008. Virus titers in the lungs were determined on day 3 after infection. The black bars indicate mean values. The body weight
curves represent mean ± 95% confidence interval of the mean. For (A) and (B), statistical analysis was performed by log-rank test. For (C) and (D), comparisons are
by area under the curve (AUC) analysis. For (E) and (F), statistical analysis was performed by t test. *P < 0.05, **P < 0.01, and ***P < 0.001, compared to the control
IgG–treated group.5 of 12
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C12G6 recognizes a highly conserved epitope that overlaps
with the RBS domain of influenza B HA
The strong HI activity of C12G6 suggests that the epitope targeted by
C12G6 is located at the top of the HA head. To further understand the
molecular basis underlying the C12G6 recognition of HA proteins in
the influenza B viruses and identify key residues recognized by this an-
tibody, we generated C12G6-induced escape mutants of influenza B
viruses by culturing the viruses in the presence of C12G6. Viruses that
grew in such conditions were harvested, and the entire HA sequence of
these viruses was determined. Two escape mutants of B/Singapore/3/
1964 (G156R and G156E) and three escape mutants of the B/HongShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017Kong/537/2009–like virus (G156W,
P176Q, and T183K) were generated (Fig.
6A). All of the mutant residues are located
either in or near theHARBS of influenza B
(19). G156 and P176 are highly conserved
(both 100%) among all available HA se-
quences of influenza B in the NCBI
database. The residue at position 183 in
all influenza B viruses is either T or N.
The T183 variant occurs in 32.4% of influ-
enza B virus strains, whereas all other virus
strains, including B/Florida/4/2006 and B/
Massachusetts/02/2012-like, exhibit N183;
both T183 and N183 variants are sensitive
to neutralization by C12G6 (Fig. 1D). In
contrast, the T183Kmutation has not been
observed in any naturally arising influenza
B isolates. Because escape mutants raised
against anti–HAhead antibodies may af-
fect the viral fitness in vivo (20), we also
compared the pathogenicity of wild-type
(WT) and escape mutant B/Hong Kong/
537/2009-like viruses in vivo. Whereas
WTB/HongKong/537/2009–like virus in-
fection caused 100% mortality, considera-
ble body weight loss, and high lung viral
titers, all mice infected with the three mu-
tant viruses survived, with only slight body
weight loss and lower lung viral titers (fig.
S17).
We next determined the epitope tar-
geted by C12G6 using a molecular dock-
ing strategy. The candidate epitope residues
were determined on the basis of three-
dimensional HA trimer models, which
indicated the presence of the epitope at the
top of the HA head and its overlap with
the RBS region (Fig. 6B). On the basis
of the conservation analysis, most of the
amino acids within the epitope are more
than 98%conserved (in green), and the re-
mainder is 75 to 98% conserved (in yel-
low) in all 2000 full-length influenza B
HA sequences in the NCBI database
(Fig. 6B). To further characterize the
C12G6 epitope, we selected nine potential
C12G6-contacting residues on B/Brisbane/
60/2008 HA for single-point mutationalanalysis based on the escapemutant results and calculation and filtering
for surface interaction (table S9). We expressed these HA mutants on
humanembryonic kidney (HEK) 293Tcells and tested forC12G6binding
by flow cytometry. Three HA mutants (P159A, N163A, and Q249A)
bound C12G6 similarly to the WT HA, whereas six of the nine HA mu-
tants (G156W, P176Q, T183K, K86A, G254A, and S258A) showed re-
duced C12G6 binding (Fig. 6C). Of these, G156W, K86A, and G254A
almost abolished binding, whereas the other three mutations decreased
binding by less than fourfold. Consistent with the flow cytometry results,
G156W, P176Q, and T183K escape mutant viruses also revealed reduced
C12G6 binding when tested by ELISA (fig. S18). These results identifiedFig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. (A and B) Kaplan-Meier
survival curves of mice that received C12G6 (10 mg/kg) (open symbols), oseltamivir (25 mg/kg) (closed symbols), or
C5G6 (25 mg/kg) (no symbols) at the indicated day after intranasal infection with 25 MLD50 of MA-B/Florida/4/2006
(A) or MA-B/Brisbane/60/2008 (B). The control IgG is C5G6. dpi, days postinfection. (C to H) Survival curves (C and D),
body weight change (E and F), and lung viral titers (G and H) of BALB/c mice (n = 5 per group) that received a single
treatment of C12G6 or a control IgG (C5G6) intravenously at 2 mg/kg, oseltamivir orally at 25 mg/kg twice a day for
4 days, or a combined treatment of C12G6 and oseltamivir, starting from 2 days after intranasal infection with 25 MLD50
of MA-B/Florida/4/2006 or B/Brisbane/60/2008. The virus titers in lungs were determined on days 4 and 6 after infection.
The black bars indicate mean values. The body weight curves represent mean ± 95% confidence interval of the mean.
Statistically significant difference of the survival outcome was estimated with the log-rank test. The AUC analysis was
used to determine the significance of body weight loss, and the t test was used to assess the significance of lung viral
titers. *P < 0.05, **P < 0.01, and ***P < 0.001, compared to the control IgG–treated group.6 of 12
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six potential keyC12G6 epitope residues and are colored in red in Fig. 6D.
We then compared the differences between the epitopes recognized by
C12G6 and CR8033 antibodies (17 ); the two epitopes are distinct butShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017overlap to a certain degree in the RBS do-
main (Fig. 6E). As shown in competition
ELISA assay, C12G6 overlapped with
the RBS-targeted CR8033-like antibody
epitope by competing for binding with
the CR8033-like antibody but did not
compete for binding to HA with the
CR9114-like antibody (Fig. 6F).
C12G6 targets influenza B through
multiple inhibition mechanisms
Consistent with the HI activity exerted by
C12G6 against both influenza B lineages,
cross-lineage inhibition of viral infec-
tion by C12G6 was observed after pre-
incubation with either B/Florida/4/2006
(Yamagata) or B/Brisbane/60/2008 (Victoria)
virus (Fig. 7A), indicating that C12G6 has
the ability to prevent influenza B virus
entry into cells. To determine whether
C12G6 inhibits influenza B viral egress
from infected cells, we measured influen-
za B virus antigens (using polyclonal rab-
bit sera against the respective virus) present
in the supernatants and lysates of MDCK
cells infected with either B/Florida/4/
2006 (Yamagata) or B/Brisbane/60/2008
(Victoria) virus, where different concen-
trations of antibodies were added 4 hours
after infection, before further incubation.
Viruses were present in all cell lysates
but were only detected in the supernatants
of infected MDCK cell cultures incubated
with a control antibody or a low concen-
tration of C12G6. No virus was detected
in supernatants incubated with C12G6
(2 mg/ml) despite a strong virus band in
the lysate (Fig. 7B), indicating that C12G6
inhibits viral egress from infected cells
for both influenza B lineages.
We next tested whether C12G6 has
the inhibition mechanisms generally ob-
served in stem-binding antibodies. Acti-
vation of HA-mediated membrane fusion
requires trypsin-mediated cleavage of
the precursor, HA0, and exposure of the
cleaved HA to the low pH of endosomes.
For the HA0 activation inhibition assay,
HA0 protein was incubated with the anti-
bodybefore exposure toTPCK(tosylphenyl-
alanyl chloromethyl ketone)–treated trypsin
for 0, 5, 10, 20, or 40min.Western blot anal-
ysis showed that C12G6 did not block
trypsin-mediated HA0 activation because
the HA0 protein was rapidly cleaved by
trypsin in the presence of C12G6 (fig. S19).We also performed a pH-induced protease sensitivity immunoblot assay
to determine whether C12G6 inhibits membrane fusion in both
lineages of influenza B viruses. Exposure to low pH converts the HAsFig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets. (A to D) Virus titers in nasal washes from
ferrets treated with C12G6 (20 mg/kg) or control antibody (C5G6) 1 day before (prophylactic groups) or after (thera-
peutic groups) intranasal infection with 1 × 107 TCID50 of B/Florida/4/2006 (A and B) or B/Brisbane/60/2008 (C and D).
(E to H) Changes in body temperatures of ferrets treated with C12G6 (20 mg/kg) or control antibody (C5G6) 1 day
before (prophylactic groups) or after (therapeutic groups) intranasal infection with 1 × 107 TCID50 of B/Florida/4/2006
(E and F) or B/Brisbane/60/2008 (G and H). Nasal washes were collected on the indicated days and titrated by TCID50
assay. Body temperatures are expressed as the percentage of baseline values. The black bars indicate mean values.
Statistical analysis was performed by t test. *P < 0.05, compared to the control IgG–treated group.7 of 12
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to the postfusion state, rendering them sensitive to trypsin digestion. No-
tably, C12G6 binding to FL/2006HAor BR/2008HAprevented the low
pH–induced conformational change, which is required for membraneShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017fusion, by stabilizing the prefusion confor-
mation (Fig. 7C). Because it is very rare for
an anti-head antibody to inhibit mem-
brane fusion,we conducted cell-cell fusion
and red blood cell fusion assays to validate
this C12G6 neutralization mechanism.
These two assays confirmed that C12G6
blocked the membrane fusion of viruses
from both lineages (figs. S20 and S21).
Because protective efficacy of HA
bnAbs largely depends on antibody effec-
tor functions (12, 14), we finally evalu-
ated the ADCC, complement-dependent
cytotoxicity (CDC), and antibody-dependent
cellular phagocytosis (ADCP) activities of
C12G6 against B/Lee/1940-, B/Florida/4/
2006-, or B/Brisbane/60/2008-infected
cells. For the ADCC and CDC assay, we
produced an Fc mutant of C12G6 that
lacked Fc receptor binding activity (C12G6-
LALA) (12) as a negative control anti-
body. C12G6-LALA exhibited the same
binding and in vitro neutralizing prop-
erties as C12G6 (fig. S22 and table S10)
and a comparable half-life in vivo (fig. S23).
To benchmark C12G6 effector functions
against antibodies directed toward other
sites of the HA, we included CR8033-like,
CR8071-like, CR9114-like, and C5G6 anti-
bodies as controls. C12G6 demonstrated
weak ADCC activity against B/Lee/1940,
no ADCC activity against B/Florida/4/
2006, and comparably high ADCC ac-
tivity against B/Brisbane/60/2008. In
contrast, CR8033-like antibody only dis-
played comparably weak ADCC activity
against the Victoria strain, whereas CR8071-
like and CR9114-like antibodies exhibited
strong ADCC activities against all three
viruses, and C12G6-LALA and C5G6 anti-
bodies only showed background levels
of activity (fig. S24A and Fig. 7, D and E).
Unexpectedly, C12G6, along with CR8071-
like and CR9114-like antibodies, showed
high CDC activity against all three virus
strains. In contrast, C12G6-LALA and
control IgG did not reveal any CDC ac-
tivity (fig. S24B and Fig. 7, F and G).
The antibody effector functions of C12G6
were further verified in in vivo protec-
tive efficacy experiments. The results also
indicated that the in vivo efficacy of
C12G6 is partially dependent on anti-
body effector functions (fig. S25). Finally,
we demonstrated that 12G6 could not
induce any ADCP activity against influ-enza B in the mouse model (fig. S26). Thus, C12G6 becomes a mul-
timechanistic cross-lineage therapeutic antibody targeting the HA
head of influenza B virus (fig. S27 and table S11).Fig. 6. Epitope mapping of C12G6. (A) Amino acid substitutions found in the HA of C12G6-induced escape mu-
tants. (B) Surface representation illustration and conservation analysis of the neutralizing epitope recognized by
C12G6 on the HA trimer model of B/Brisbane/60/2008 (Protein Data Bank code: 4FQM) using the DS Visualizer 1.7.
The epitope was determined using a molecular docking strategy. One HA protomer of the HA trimer is colored in
cyan, whereas the other two protomers are colored in gray. The residues are colored according to the conservation
of contact residues across all available influenza B virus sequences: green, more than 98% conserved; yellow, 75 to
98% conserved. Residue numbers are shown, with RBS residues in red and others in black. (C) Reactivity of C12G6
with WT or mutant BR/2008 HAs expressed in HEK293T cells. The mean fluorescence intensities (MFIs) from flow
cytometry profiles are shown. Mock, mock-transfected cells. *P < 0.05, compared to the WT group. Statistical anal-
ysis was performed by t test. (D) Illustration of the identified key C12G6 epitope residues, colored in red, with the
RBS domain colored in blue. The residue numbers with amino acid substitutions found in the C12G6 escape mu-
tants are shown in red, and others are shown in black. (E) Comparison of C12G6 and CR8033 contact residues on
influenza B HA. Brown, contact residues unique to C12G6; blue, contact residues unique to CR8033; light yellow,
common contact residues of both antibodies. The residue numbers are shown, with RBS residues in red and others
in black. (F) Comparison of epitopes of C12G6 and two representative bnAbs (CR8033-like and CR9114-like anti-
bodies) using a competition ELISA test. C12G6 was used as a competitor, and C5G6 was used as a negative control.
*P < 0.05, compared to the control group.8 of 12
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We report an anti–influenza B bnAb, C12G6, directed against the head
of HAwith higher potency and broader breadth of anti-influenza activ-
ity in vitro and in vivo than four other antibodies previously reported
(16, 17). Stronger antiviral activity was still observed even when C12G6
treatment was delayed until day 3 or 5 after influenza B infection. Coad-
ministration of C12G6 and oseltamivir improved protective efficacy,
compared to either treatment alone, possibly by synergistically targeting
distinct viral functions associated with different stages of the viral life
cycle. Thus, C12G6 appears to be a promising candidate for the devel-Shen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017opment of broad-spectrum therapeutics against influenza B infection
and may inform the design of a universal influenza vaccine.
The development of bnAbs targeting the highly variable epitopes on
the HA head is difficult. This study demonstrated that the influenza B
bnAbs can be generated frommice sequentially immunized with live B/
Florida/4/2006 (Yamagata) and B/Brisbane/60/2008 (Victoria) viruses
via the intranasal route. Another study, using intramuscular immuni-
zation, reported that primingwithVictoria andboostingwithYamagata
induced more responses to both lineages than priming with Yamagata
and boosting with Victoria (21). It has been shown that the route ofFig. 7. Inhibitory mechanisms of C12G6. (A) MDCK cells were inoculated with B/Florida/4/2006 (FL/2006) or B/Brisbane/60/2008 (BR/2008) viruses preincubated with
C12G6 or polyclonal rabbit sera, as indicated. The expression of influenza B nucleoprotein in MDCK cell monolayers 16 to 18 hours after inoculation was detected by
immunofluorescence. Green, infected cells positive for NP protein; blue, 4′,6-diamidino-2-phenylindole staining. (B) Immunoblots of influenza B detected in the lysates
and supernatants of MDCK cells infected with B/Florida/4/2006 or B/Brisbane/60/2008 and subsequently incubated with different concentrations of C12G6, as indicated.
Influenza B was detected using rabbit sera against B/Florida/4/2006 and B/Brisbane/60/2008, respectively. (C) C12G6 protects HAs of B/Florida/4/2006 and B/Brisbane/
60/2008 from the pH-induced protease sensitivity associated with membrane fusion. (D to G) ADCC (D and E) or CDC (F and G) activities of the indicated antibodies
against B/Florida/4/2006 virus– and B/Brisbane/60/2008 virus–infected MDCK cells, respectively. The bars represent the mean ± SEM. *P < 0.05, compared to the control
IgG group.9 of 12
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administration strongly influences both the quantity and quality of
vaccine-induced immunity (22, 23). Thus, a rational design for sequen-
tial and mucosal immunization strategies has the capability to produce
broadly neutralizing and highly potent immune response.
Four influenza B HA bnAbs (CR8033, CR8071, CR9114, and 5A7),
which show cross-lineage neutralization and protective activity, have
been previously reported (16, 17). Of these four antibodies, C12G6 is
most similar to CR8033 in that both bind to the RBS domain in the
HA head. Remarkably, C12G6 exhibited distinct HI activity against in-
fluenza B virus strains when compared to CR8033-like antibody, sug-
gesting that it recognizes an epitope distinct from that recognized by the
CR8033. C12G6 targets an epitope that overlaps with the RBS domain
and is overlapped by the CR8033-like epitope, as determined by epitope
mapping of C12G6 with escape andHAmutants. However, the epitope
targeted byC12G6 is completely distinct from those targeted byCR8071-
like, CR9114-like, and 5A7-like antibodies. It has been previously re-
ported that escape mutants raised against anti–HA head antibodies
can gain pathogenicity (23). In contrast, we found that the escape mu-
tants raised against C12G6 showed reduced fitness in vivo, highlighting
that the mutant residues of C12G6 epitope are critically important for
viral replication. Therefore, the breadth and potency of the activity of
C12G6 should be related to a vulnerable, highly conserved HA head ep-
itope in the influenza B virus.
C12G6 showed better in vivo efficacy than CR8033, although they
seem to have a similar epitope. C12G6 exerts its neutralization effects by
directly inhibiting binding to an epitope that overlaps the RBS domain.
Such direct inhibition of viral binding to host receptors is generally crit-
ical for virus neutralization (17). C12G6 inhibited the tested viruses even
after infection. Specifically, C12G6 blocked low pH–induced viral
fusion with endosomal membranes, which is a key event in the viral
replication cycle. This function is generally observed among antibodies
targeting the HA stem (12, 14) and is seldom seen in CR8033-like anti-
bodies targeting the HA head (16). The C12G6 epitope is somewhat
closer to the stem region of HA than CR8033, which may be related
to functions generally displayed by HA stem–targeting antibodies.
Thus, C12G6 bindingmay target a truly unusualmotif on theHAhead,
disturbing low pH–dependent structural changes inHAand preventing
viral replication. Furthermore, similar to CR8033-like antibody, C12G6
is able to inhibit virus replication by blocking the release of progeny vi-
rions from infected cells, an effect resembling that exerted by neuramin-
idase inhibitors (17). Notably, in addition to directly neutralizing
viruses, we observed that C12G6 triggered the Fc-mediated viral clear-
ance mechanisms, ADCC and CDC. Two recent papers found that
binding of the HA to sialic acid on the effector cell is crucial for ADCC
activity (24, 25); thus, ADCC activity may be blocked by HI active anti-
bodies. For the three viruses tested, C12G6 showed no ADCC activity
against B/Florida/4/2006, weak ADCC activity against B/Lee/1940, and
comparably high ADCC activity against B/Brisbane/60/2008. Con-
versely, C12G6 exhibited high HI activity against B/Florida/4/2006,
moderately high HI activity against B/Lee/1940, and relatively lower
HI activity against B/Brisbane/60/2008. Thus, the ADCC activity of
C12G6 against these three viruses revealed an opposite trend to that
of its HI activity, consistent with reports that HI active antibodies can
block ADCC activity (24, 25). C12G6 also induced strong CDC activity
against all three influenza B virus lineages. By contract, CR8033
displayed very weak ADCC and CDC responses against influenza B
viruses. Hence, the better protective efficacy of C12G6 is likely attribut-
able to its more comprehensive antiviral mechanisms, which, together,
inhibit influenza B viral infection.Shen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017There are some limitations of this study: (i) The relatively few repre-
sentative influenza B virus strains isolated between 1964 and 2001 are
available for the characterization of antibodies, which limit more
complete spectrum characterization of the breadth and potency activity
of the bnAbs; (ii) the HI and neutralization activity of C12G6 against
some representative influenza B viruses was not strong enough, but we
could not determine whether the variation in HI and neutralization ac-
tivity may affect the protective efficacy of C12G6 in vivo; and (iii) the
detail structure of the epitope bound by C12G6 has not been revealed.
Further studies are necessary to delineate the molecular basis of the
binding epitope bound by C12G6 for understanding its potent and
broad viral clearance activities.MATERIALS AND METHODS
Study design
The objective of this study was to develop bnAbs that neutralize mul-
tiple lineages of influenza B viruses and potently cross-protect against
influenza B virus infection. A variety of immunization approaches using
different antigenic lineages of influenza B strains were combined with a
panel of functional screeningmethods to generatemultiple cross-reactive
mAbs using the murine hybridoma technique. One bnAb, C12G6,
was generated and evaluated in vitro and in vivo and verified to be
a promising candidate for the development of prophylactics or thera-
peutics against influenza B. All in vivo studies were performed in ac-
cordance with Institutional Animal Care and Use Committee guidelines
and were approved by the Ethics Committee of Xiamen University Lab-
oratory Animal Center. Six-week-old female BALB/c mice were pur-
chased from Shanghai Silaike Laboratory Animal Co. Ltd. and were
used for all experiments. Ferrets were purchased from Wuxi Sangosho
Biotechnology Co. Ltd. The animals weremaintained in individually ven-
tilated cages and monitored closely for survival and signs of illness for up
to 14 days after challenge. The guidelines for humane end points were
strictly followed for all in vivo experiments; animals that lost more than
25% of their initial body weight were immediately euthanized by CO2
asphyxiation and were recorded as nonsurvivors. All animals were ran-
domly assigned to treatment groups using a randomization tool imple-
mented in Microsoft Excel. The pathologists who evaluated the tissue
sections were blinded to treatment groups. All in vitro and in vivo
experiments were repeated at least three times, unless otherwise stated
within the figure legends. The inhibitory mechanisms of C12G6 were
further investigated to determine the prophylactic or therapeutic
potential of C12G6 for future clinical applications. All HA sequences
of influenza B viruses used in this study are listed in table S12. Primary
data are located in table S13.
Prophylactic and therapeutic efficacy studies in mice
In a prophylactic setting, groups of five female BALB/c mice aged 6 to
8 weeks were injected intravenously with 200 ml of vehicle control or a
dose of C12G6 (5, 1.7, 0.6, 0.2, or 0.06 mg/kg). One day later, the mice
were deeply anesthetized with isoflurane and oxygen and challenged
intranasally with 25 MLD50 of MA-B/Florida/4/2006 (Yamagata),
MA-B/Brisbane/60/2008 (Victoria), or MA-B/Lee/1940 (earlier) virus,
which was grown in MDCK cells using standard viral culturing tech-
niques. In a therapeutic setting, the mice received the antibody or osel-
tamivir at the indicated doses at 1, 3, or 5 days after infection. The lungs
of mice were collected for virus titration at 3 or 6 days after infection.
Tissuewas collected forhistopathological evaluation4days after infection.
For oseltamivir comparison studies, mice were administered oseltamivir10 of 12
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(25mg/kg) orally twice daily for 4 days. For the coadministration study,
the mice received a single treatment of C12G6 or C5G6 antibodies in-
travenously at 2 mg/kg (with water administered orally to mimic the
oseltamivir treatment), oseltamivir orally at 25 mg/kg twice a day for
4 days [accompanied by a single dose of control IgG (2 mg/kg)], or a
combined treatment of C12G6 and oseltamivir starting at 2 days after
infection. The animals were observed daily formortality andmorbidity,
and body weight was measured for up to 14 days after infection.
Animals that lost more than 25% of their initial body weight were eu-
thanized in accordance with our animal ethics protocol. To characterize
the effects of the Fc fragment on the protection ability of C12G6, groups
of five female BALB/c mice aged 6 to 8 weeks were injected intra-
venously with C12G6 (1 or 10 mg/kg), C12G6-LALA (1 or 10 mg/kg),
or control IgG (20 mg/kg) 1 day after infection with a lethal dose of
MA-B/Brisbane/60/2008. The mice were monitored daily, as de-
scribed in the above protocol.
Prophylactic and therapeutic efficacy studies in ferrets
Fourteen-week-old male ferrets, certified by the supplier to be free of
any evidence of infectious, contagious, or communicable disease, were
housed in study groups of four. All ferrets were moved to the biosafety
level 2 laboratories at least 14 days before the experiment for acclima-
tization, andbaseline bodyweight and temperature levelsweremeasured
for at least 7 days before the assay. Tomeasure body temperature of fer-
rets, they were subcutaneously implanted with a microchip (implant-
able, programmable temperature transponder IPTT-300, Bio Medic
Data Systems) between the shoulder blades, with subcutaneous body
temperature measured by the microchip and data reported by the tran-
sponder chip twice a day. For the prophylactic studies, ferrets were an-
esthetized with isoflurane and oxygen and injected intravenously with
C12G6 (20 mg/kg) or control antibody. Twenty-four hours later, ferrets
were anesthetized with isoflurane and received 500 ml of the virus per
naris (1 ml in total containing 1 × 107 TCID50). For the therapeutic
studies, ferrets received the same virus a day before intravenous injection
withC12G6or control antibody.Virus stockwas prepared from infected
MDCKcells. Ferretswere held uprightwith their head tilted slightly back
for about 1 min after virus administration to reduce the likelihood of
inoculum dripping from the nares. Ferrets were then returned to their
home cage and observed for righting reflex. We measured the tempera-
ture of ferrets twice a day, at 8:00 a.m. and 8:00 p.m., and collected nasal
washes each day. Ferrets were observed twice daily, with nasal discharge,
sneezing, activity level, and weight being measured on day 0, before in-
fection, and each day thereafter. The activity level scoring protocol was
adapted from that described by Reuman et al. (26): 0, alert and playful;
0.5, alert but playful only when given incentives; 1, alert but not playful
when given incentives; 2, neither alert nor playful even when given
incentives.
Statistical analysis
The bars in this study represent the mean ± SEM for three repeated
experiments. To establish significant differences for survival curves,
we used the log-rank test in GraphPad Prism 6.0. Statistical analysis
of body weight was performed using the AUC analysis, as described
previously (17). Briefly, the weight of each mouse at day 0 was used as
the baseline, and the weight change was determined relative to the
baseline. The AUC was defined as the summation of the area above
and below the baseline. Themean AUC values were compared by anal-
ysis of variancewithDunnett’s T3 adjustment formultiple comparisons.
Statistical analyses were performed with SPSS software. Virus titrationShen et al., Sci. Transl. Med. 9, eaam5752 (2017) 18 October 2017data for infected mice and the ADCC and CDC experiments were ana-
lyzed using multiple t tests in GraphPad Prism 6.0. P values reported in
the figures and figure legends indicate the following significance levels:
*P < 0.05, **P < 0.01, and ***P < 0.001.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/412/eaam5752/DC1
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Fig. S1. A schematic diagram showing the 12G6 generation and selection process.
Fig. S2. In vitro binding and neutralization activities of mouse antibody 12G6.
Fig. S3. Nucleotide and amino acid sequences of the VH and VL chain regions of C12G6.
Fig. S4. Binding curves for reported Kd values for binding of C12G6 to influenza B HAs.
Fig. S5. Immunofluorescence assay activity of C12G6 against both lineages of influenza
B viruses.
Fig. S6. Binding of C12G6 to MDCK cells infected with influenza B viruses, detected by flow
cytometry.
Fig. S7. C12G6 binds the B/Florida/4/2006 HA subunit in Western blotting.
Fig. S8. Expression, purification, and characterization of influenza B HA bnAbs.
Fig. S9. In vitro neutralization activities (IC50 values) of C12G6 and other reported influenza
B HA bnAbs.
Fig. S10. Body weight change curves of mice treated with C12G6 before or after challenge with
influenza B viruses.
Fig. S11. Immunofluorescence assay activity of anti–influenza B nucleoprotein mAb 4D5
against both lineages of influenza B viruses.
Fig. S12. Histological analysis of lungs from mice prophylactically treated with C12G6 before
infection with influenza B viruses.
Fig. S13. Histological analysis of lungs from mice therapeutically treated with C12G6 after
infection with influenza B viruses.
Fig. S14. Comparison of therapeutic effects of C12G6 and oseltamivir against influenza
B infection in mice.
Fig. S15. Body weight change curves of ferrets treated with C12G6 before or after challenge
with influenza B viruses.
Fig. S16. Clinical sign of ferrets after prophylactic and therapeutic treatment with C12G6
against influenza B infection.
Fig. S17. In vivo fitness of mutant B/Hong Kong/537/2009–like viruses.
Fig. S18. Reactivity of C12G6 with WT or mutant B/Hong Kong/537/2009–like viruses in ELISA.
Fig. S19. C12G6 does not block HA0 activation.
Fig. S20. C12G6 inhibits syncytia formation.
Fig. S21. Red blood cell fusion assay.
Fig. S22. Comparison of the in vitro binding and neutralizing properties of C12G6 and
C12G6-LALA.
Fig. S23. Serum antibody concentrations after C12G6 or C12G6-LALA treatment.
Fig. S24. ADCC and CDC activities of C12G6 against the B/Lee/1940 virus strain.
Fig. S25. Determination of the role of antibody effector functions in the protective efficacy of
C12G6.
Fig. S26. ADCP activity of 12G6 against influenza B viruses.
Fig. S27. A schematic diagram showing the inhibition mechanisms of C12G6.
Table S1. ELISA EC50 and SD values of mouse antibodies 12G6 and 5G6, related to fig. S2.
Table S2. The full designations and abbreviations of the influenza virus strains used in this study.
Table S3. ELISA EC50 and SD values of C12G6 and C5G6 antibodies, related to Fig. 1B.
Table S4. Kd for binding of C12G6 to HAs of influenza B strains.
Table S5. ELISA EC50 and SD values of the indicated antibodies, related to fig. S8B.
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Fig. 1D.
Table S7. Neutralization IC50 and SD values of CR8071-like and CR9114-like antibodies, related
to Fig. 1D.
Table S8. Neutralization IC50 and SD values of 5A7-like and C5G6 antibodies, related to Fig. 1D.
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Table S13. Primary data.
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effective in mice and ferrets. This antibody could be widely deployed to treat or prevent influenza B infection 
the receptor binding site in hemagglutinin, a region critical to viral entry, and was shown to be therapeutically
have now generated a potent antibody that inhibits diverse strains of influenza B virus. The antibody recognizes 
.et alvaccine, influenza B is far less well studied than its cousin, influenza A, and therapeutics are lacking. Shen 
Although it circulates globally and is prevalent enough to warrant inclusion in the seasonal influenza
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